Cargando…

Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies

BACKGROUND: Tacrolimus is the most commonly prescribed medication in initial immunosuppressive regimens to prevent acute rejection in kidney transplant recipients (KTRs). Tacrolimus was originally available as an immediate-release formulation (IR-Tac) given twice daily. Extended-release tacrolimus (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vadcharavivad, Somratai, Saengram, Warangkana, Phupradit, Annop, Poolsup, Nalinee, Chancharoenthana, Wiwat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900208/ https://www.ncbi.nlm.nih.gov/pubmed/31713065 http://dx.doi.org/10.1007/s40265-019-01217-7

Ejemplares similares

Correction to: Once-Daily versus Twice Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies
por: Vadcharavivad, Somratai, et al.
Publicado: (2019)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation
por: Bzeizi, Khalid Ibrahim, et al.
Publicado: (2021)

A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients
por: Ferhatoglu, Murat Ferhat, et al.
Publicado: (2021)

Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients
por: Hurwitz, Jason T, et al.
Publicado: (2021)

Effects of Converting Tacrolimus Formulation from Twice-Daily to Once-Daily in Liver Transplantation Recipients
por: Thorat, Ashok, et al.
Publicado: (2014)

Pharmacokinetics of Once‐Daily Extended‐Release Tacrolimus Tablets Versus Twice‐Daily Capsules in De Novo Liver Transplant
por: DuBay, Derek A., et al.
Publicado: (2019)

Efficacy and safety of a switch from twice-daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients
por: Kim, Jong Man, et al.
Publicado: (2021)

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization
por: Ho, Bing, et al.
Publicado: (2019)

Comparative Long-Term Renal Allograft Outcomes of Recurrent Immunoglobulin A with Severe Activity in Kidney Transplant Recipients with and without Rituximab: An Observational Cohort Study
por: Chancharoenthana, Wiwat, et al.
Publicado: (2021)

The effect of Maintenance Treatment with Twice-daily or Prolonged Once-daily Tacrolimus Formulation on Visual Evoked Potentials in Stable Kidney Transplant Recipients
por: Kolonko, Aureliusz, et al.
Publicado: (2020)

Comparison of Tacrolimus Intra-Patient Variability during 6–12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers
por: Nuchjumroon, Almas, et al.
Publicado: (2022)

Comparison of once daily versus twice daily olmesartan in patients with chronic kidney disease
por: Sakai, Yukinao, et al.
Publicado: (2013)

Medium-Term Renal Function in a Large Cohort of Stable Kidney Transplant Recipients Converted From Twice-Daily to Once-Daily Tacrolimus
por: Guirado, Lluís, et al.
Publicado: (2015)

Safety and Efficacy of Conversion from Twice-Daily Tacrolimus to Once-Daily Tacrolimus One Month after Transplantation: Randomized Controlled Trial in Adult Renal Transplantation
por: Oh, Chang-Kwon, et al.
Publicado: (2014)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
por: Bunnapradist, S, et al.
Publicado: (2013)

Risk Factors for the Adverse Events after Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplantation Patients
por: Suh, Suk-Won, et al.
Publicado: (2016)

Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study
por: Lapeyraque, Anne-Laure, et al.
Publicado: (2014)

Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients
por: Gaber, A. Osama, et al.
Publicado: (2013)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial
por: Faravardeh, Arman, et al.
Publicado: (2021)

Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study
por: Monchaud, Caroline, et al.
Publicado: (2023)

The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
por: Zaltzman, Alina S. R, et al.
Publicado: (2016)

Therapeutic drug monitoring of modified release once daily tacrolimus in de novo renal transplant with conversion to a twice daily generic in the stable period
por: Mathew, Binu Susan, et al.
Publicado: (2015)

Agreement and Precision Analyses of Various Estimated Glomerular Filtration Rate Formulae in Cancer Patients
por: Chancharoenthana, Wiwat, et al.
Publicado: (2019)

Gastrointestinal manifestations of long-term effects after COVID-19 infection in patients with dialysis or kidney transplantation: An observational cohort study
por: Chancharoenthana, Wiwat, et al.
Publicado: (2023)

A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers
por: Zaltzman, Jeffrey S, et al.
Publicado: (2014)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
por: Woodcock, Ashley, et al.
Publicado: (2011)

Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
por: Yun, Ji Young, et al.
Publicado: (2013)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety
por: Derington, Catherine G., et al.
Publicado: (2020)

A randomized trial of once daily versus twice daily dosing of oral iron in CKD
por: Sood, Vivek, et al.
Publicado: (2023)

Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation
por: Doesch, Andreas O, et al.
Publicado: (2013)

Update on the clinical utility of once-daily tacrolimus in the management of transplantation
por: Posadas Salas, Maria Aurora, et al.
Publicado: (2014)

Update on the clinical utility of once-daily tacrolimus in the management of transplantation
por: Revollo, Jane
Publicado: (2015)

The effect of the very low dosage diltiazem on tacrolimus exposure very early after kidney transplantation: a randomized controlled trial
por: Susomboon, Teerada, et al.
Publicado: (2022)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Bioequivalence of twice-daily oral tacrolimus in transplant recipients: More evidence for consensus?
por: Ball, Simon
Publicado: (2017)

Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure
por: Anand, Inder S, et al.
Publicado: (2010)

Tacrolimus dose adjustment is not necessary in dose to dose conversion from a twice daily to a prolonged release once daily dose form
por: Tiankanon, Kanitha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fmu5gfqtlm0ofrsrpof5hgq7lm